Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5635038 | 0.90 | LMNA (0.48) | GAAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL5634607 | 0.90 | GAA (0.44) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL5635059 | 0.81 | GAA (0.35) | GAAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL5634647 | 0.78 | LMNA (0.31) | GAAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL5635601 | 0.77 | MAPT (0.42) | GAAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL5634619 | 0.76 | ALDH1A1 (0.38) | GAAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL2959423 | 0.76 | LMNA (0.44) | GAAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL2959759 | 0.76 | LMNA (0.48) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL8513843 | 0.75 | GAA (1.00) | GAAALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL11542705 | 0.74 | GAA (0.73) | GAAALDH1A1MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179830-B2 | Substituted thienoimidazoles useful for disease treatment and prevention | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-20 | — | — | US | disclosed |
| US-20050075385-A1 | Substituted thienoimidazoles useful for disease treatment and prevention | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075385-A1 | Substituted thienoimidazoles useful for disease treatment and prevention | TPMT, TYMS, SLC19A2 | GAA 2119/4885ALDH1A1 595/4885MAPT 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.